Abstract:Purpose: To evaluate the accuracy and the predictive value of 18F-FDG PET or PET/CT in the assessment of neoadjuvant chemotherapy (NAC) in locally advanced breast cancer by meta-analysis. Materials and Methods: Relevant studies were identified by systematic searches of PUBMED and COCHRANE databases, published in English. To ensure homogeneity of all included studies, selection criteria were established and all the studies were scored according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria. Meta-analysis was done on the diagnostic performance data from eligible studies. Draw funnel plots to explore the publication bias. Draw forest plots to exclude abnormal data(s). Use Spearman correlation coefficients p, likelihood ratio x2 test and I2 index in order to indicate heterogeneity. Estimate and compare the weighted summary sensitivities (SEs), specificities (SPs), diagnostic odds ratios (DORs), and summary receiver operating characteristic (SROC) curves of PET and other examinations (measuring the size of tumor). Subgroup analyses were performed to identify heterogeneity potential sources. Do Z test to find significant difference between each results. Results: 27 groups of data in 19 eligible studies were included with a total of 1164 subjects evaluated by 18F-FDG PET or PET/CT and 291 ones evaluated by other examinations. Funnel plots showed the existence of publication bias. Spearman correlation coefficients p, likelihood ratio x2 test and I2 index explored the heterogeneity. The Results of the Weighted Summary: SEPET was significantly higher than SED [83.7% (329/393) vs. 59.0% (98/166), p SPPET was significantly higher than SPD [66.8% (512/766) vs. 40.8% (51/125), p DORPET was significantly higher than DORD (14.02 vs. 1.29, p AUCPET and Q*PET were both significantly higher than AUCD and Q*D (AUCs 0.8838 vs. 0.6046; Q*s 0.8143 vs. 0.5788, p st or 2nd cycle of NAC was a litter better than later with higher SE (p = 0.083). Standardized uptake value (SUV) reduction rate between 40% and 45% as FDG-PET response threshold value was used for its highest SP (p = 0.01), while no significant difference was found comparing SEs and DORs (p > 0.05). Trend of higher SE and lower SP were found at ER negative breast cancers than ER positive ones (SEs 93.94% vs. 83.33%; SPs 35.76% vs. 62.24%), though Z test did not find significant difference (p > 0.05). Conclusion: This meta-analysis showed that FDG-PET or PET/CT does have a higher global accuracy in assessing the response for NAC in breast cancer. Comparing with clinical response, metabolic response plays a potential role in directing therapy for breast cancer. Factors which affected the accuracy of FDG-PET assessment included PET timing point, SUV reduction rate as threshold value and ER expression.

Cost-effectiveness Analysis of Positron-Emission Tomography-Computed Tomography in Preoperative Staging for Nonsmall-Cell Lung Cancer with Resected Monometastatic Disease.

Cost-effectiveness Analysis of Strategies Introducing Integrated 18F-FDG PET/CT into the Mediastinal Lymph Node Staging of Non-Small-cell Lung Cancer

PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Cost-effective Analysis of PET Application in NSCLC

Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules

PET with 18F-fluorodeoxyglucose for staging of non-small cell lung cancer

Prognostic Evaluation of Patients with Non-Small Cell Lung Cancer by Using Semi-Quantitative Metabolic Parameters of 18F-FDG PET/CT

Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT

The impact of 18F-FDG PET/CT on the clinlcal strategies of patients with known or suspected lung cancer

Impact of Preoperative [18F]FDG PET/CT Vs. Contrast-Enhanced CT in the Staging and Survival of Patients with Clinical Stage I and II Non-Small Cell Lung Cancer: a 10-Year Follow-Up Study.

Clinical Value of Surgical Staging with Preoperative 18F-FDG PET/CT Evaluation for Mediastinal Lymph Nodes in Lung Cancer

Diagnostic Value of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/computed Tomography for the Detection of Metastases in Non–small‐cell Lung Cancer Patients

Predictive Value of Preoperative Pet/Ct in Resectable Clinical N0 Non-Small Cell Lung Cancer

Cost-effectiveness of Stereotactic Body Radiotherapy Versus Conventional Fractionated Radiotherapy for Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer

Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma—Reassessment based on the revised Japanese national insurance reimbursement system

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18F-FDG PET/MRI in patients with non-small cell lung cancer

The Value of 18F-FDG Positron Emission Tomography/computed Tomography on the Pre-Operative Staging and the Management of Patients with Pancreatic Carcinoma.

CT, MRI, and F-18 FDG PET for the Detection of Non-Small-cell Lung Cancer (NSCLC) A Protocol for a Network Meta-Analysis of Diagnostic Test Accuracy

[The Prognostic Impact of Preoperative PET-CT on Postoperative Recurrence for Completely Resected Stage I Non-Small Cell Lung Cancer].

Meta-Analysis: <sup>18</sup>F-FDG PET or PET/CT for the Evaluation of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer